News
SRPT
18.39
-2.96%
-0.56
Patent Settlement Clears Key Gene Therapy Risk For Sarepta Therapeutics Stock
Simply Wall St · 10h ago
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute
TipRanks · 1d ago
*Sarepta Therapeutics, Inc.: Regenxbio and UPenn Agreed not to sue Sarepta or Catalent>SRPT
Dow Jones · 1d ago
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
Benzinga · 1d ago
*Sarepta Therapeutics, Inc.: To Pay Regenxbio $39M Within Ten Days of the Effective Date of the Settlement Agreement >SRPT
Dow Jones · 1d ago
*Sarepta Therapeutics, Inc.: Entered Settlement Agreement With Regenxbio, UPenn Trustees, and Catalent >SRPT
Dow Jones · 1d ago
*Sarepta Therapeutics, Inc.: Settlement Regards, Among Other Matters, Resolution of Pending Patent Infringement Litigations >SRPT
Dow Jones · 1d ago
Weekly Report: what happened at SRPT last week (0914-0918)?
Weekly Report · 3d ago
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Seeking Alpha · 4d ago
Demand Stabilization Might Change The Case For Investing In Sarepta Stock (SRPT)
Simply Wall St · 09/17 09:30
Solid Biosciences wins new Outperform at RBC on DMD opportunity
Seeking Alpha · 09/16 16:15
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX)
TipRanks · 09/15 11:50
Sarepta Therapeutics (SRPT) Heads To Morgan Stanley, Is Most Of The Upside Already Priced In?
Simply Wall St · 09/14 13:16
Weekly Report: what happened at SRPT last week (0907-0911)?
Weekly Report · 09/14 09:03
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
TipRanks · 09/10 18:21
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
Benzinga · 09/09 14:04
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Seeking Alpha · 09/09 11:45
Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform
TipRanks · 09/08 19:45
Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’
TipRanks · 09/08 17:55
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Benzinga · 09/08 17:47
More
Webull provides a variety of real-time SRPT stock news. You can receive the latest news about Sarepta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.